Alle Storys
Folgen
Keine Story von Curasan AG mehr verpassen.

Curasan AG

euro adhoc: curasan AG
Quarterly or Semiannual Financial Statements / curasan AG announces results for first quarter Improved earnings with lower revenue

Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.
12.05.2005
Kleinostheim, May 12, 2005 - curasan AG (WKN 549 453) today announced
its financial results for the first quarter ended March 31, 2005. In
the first three months of the 2005 financial year, the company
generated revenue of EUR 1.7 million (Q1 2004: EUR 2.4 million) and a
loss before interest and taxes of EUR 400 thousand (Q1 2004: loss of
EUR 516 thousand). The net loss for the period improved to EUR 256
thousand (Q1 2004: loss of EUR 335 thousand).
Revenue was 29% lower than in the same period a year ago. In spite of
this, the company managed to improve EBIT by 22% year on year.
Production-related difficulties experienced by two of curasan’s
suppliers led to a decline in revenue in the first quarter and to an
order backlog, which is now gradually being reduced. The company was
faced with a temporary downturn in revenues within the dental market
due to the failure by the National Association of Statutory Health
Insurance Physicians and statutory health insurance companies to
reach an agreement on flat-rate allowances to be introduced in
Germany. As a direct result of protracted negotiations, health
insurers have been delaying authorisations required for cost and
treatment schedules. Market analysts expect to see an improvement in
this situation and a concomitant increase in demand in the second
half of the year. Having implemented a strict regime of cost
management, the company managed to scale back expenses further in the
first three months of 2005.  The additional measures initiated and in
some cases already executed will be stepped up in the coming months.
Thus, the management has reaffirmed its forecast of a significant
reduction in the company’s operating loss.
The full quarterly report can be accessed on the corporate website at
www.curasan.de, Investor Relations section in the course of this
afternoon.
end of ad hoc announcement
About curasan AG:
curasan AG (ISIN: DE 000 549 453 8), an exchange-listed company, is a
leading innovator within the growth market of bone and tissue
regeneration. The company has developed a comprehensive product range
centred around its synthetic bone regeneration material Cerasorb®,
for use in soft and hard tissue. curasan AG's main goal is to occupy
a leading position as a global specialist in Regenerative Medicine.
For further information, please visit curasan’s corporate website at:
www.curasan.de
end of announcement                    euro adhoc 12.05.2005 08:26:27 

Further inquiry note:

Ralph Wintermantel, curasan AG, Tel. 06027/46 86 468, e-mail:
ir@curasan.de
Dr. Erwin Amashaufer, curasan AG, Tel. 06027/46 86 0, e-mail:
ir@curasan.de

Branche: Biotechnology
ISIN: DE0005494538
WKN: 549453
Index: CDAX, Classic All Share, Prime Standard, Prime All Share
Börsen: Frankfurter Wertpapierbörse / regulated dealing
Berliner Wertpapierbörse / free trade
Hamburger Wertpapierbörse / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Niedersächsische Börse zu Hannover / free trade
Bayerische Börse / free trade
Bremer Wertpapierbörse (BWB) / free trade

Original-Content von: Curasan AG, übermittelt durch news aktuell

Weitere Storys: Curasan AG
Weitere Storys: Curasan AG